Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN US4234941031

Price
38.50 USD
Market cap
1.80 bn USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
36.18 %
Return on assets (ROA)
-32.81 %

Hemab Therapeutics Holdings, Inc. Common Stock financials

Fiscal year20242025
Revenue0.00 USD0.00 USD
Operating income-50.38 m USD-70.12 m USD
EBIT-50.38 m USD-70.12 m USD
Net income-48.71 m USD-63.91 m USD
Diluted EPS – continuing operations-1.10 USD-2.33 USD

Full history since 2024, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.